Replies to post #244571 on Biotech Values

[maverick_1]

JAMA Oncology
https://www.dr-bala.net/NWBO/jamaoncology_liau_2022.pdf

Would not be surprised with the ensuing

Partnership deals awaits.
1. Joint clinicals FUNDED by partner.
Many thousands of Checkpoint Inhibitor trials (CPI) have LOW response rates when there is a much higher response rate with NWBO’s technology platform
2) CASH Infusion
3) Significant NWBO EQUITY Interest above Mkt shr price to give NWBO Marquee status from much malignant innuendos that have been out to bury & bankrupt by so called “journalist”.

With the peer reviewed journal article
NWBO moves into a new life chapter.

Out of the Deep powerful DARK NEFARIOUS Wall St. forces and into the REAL world of complementing Big Pharma!

DIFFERENT STROKES for DIFFERENT FOLKS

[DewDiligence]

into The LIGHT(now $1.14)…for it's Moonshot?

Well, $1.14 to $0.86* is not exactly a moonshot :- )

p.s. Some NWBO longs have incorrect notions about single-arm oncology trials—see #msg-170520761.

*Today’s close.